Shots: Abbott to get non-exclusive license rights for Banyan’s TBI biomarkers, including Ubiquitin Carboxy-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) kit to utilize it on its laboratory instruments […]readmore
Tags : Abbott
Shots: The approval is based on COAPT study assessing MitraClip + medical therapy vs medical therapy as monothx. in 614 patients with moderate to severe secondary MR across 78sites including […]readmore
Shots: The companies entered into an agreement to assess insulin dose data from Novo Nordisk’ pre-filled insulin pen connected to the digital health tool marked with Abbott’s FreeStyle Libre system […]readmore
Shots: Abbott to acquire Cephea Valve, in all stock transaction, with its heart valve replacement technology The focus of the acquisition is to utilize Cephea’s technology in developing therapies for […]readmore
Shots: The approval is based on ADO II AS study results assessing the Amplatzer Piccolo in 50 patients with PDA older than three days across eight centers in the US, […]readmore
Shots: The US approval is based on MOMENTUM 3 trial results enrolling 1000 patients with NYHA Class IIIB or IV heart failure for a short-term endpoint of six months and […]readmore